Redeye raises its forecasts and Base Case following Hexatronic’s Q2 report, showing a solid sequential increase in sales, gross, and EBITA margins. While more and more points towards a market rebound in late 2024, we do not expect an as strong market as in late 2021 to mid-2023 – partly as interest rates remains rather high.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/